Ovarian cancer usually responds well to chemotherapy, but once the disease becomes resistant to chemotherapy, the treatment options available are inadequate. A number of strategies are currently undergoing clinical evaluation, among which angiogenesis and PARP [poly(ADP-ribose) polymerase] inhibitors appear promising. Pre-clinical studies have identified several potential new therapeutic strategies, and we review the potential for use of BH3 (Bcl-2 homology) mimetics, autotaxin inhibitors and statins to treat ovarian cancer.
New strategies for the treatment of ovarian cancer
Elizabeth Robinson, Natalie Fisher, Vasileios Stamelos, Charles Redman, Alan Richardson; New strategies for the treatment of ovarian cancer. Biochem Soc Trans 1 February 2014; 42 (1): 125–129. doi: https://doi.org/10.1042/BST20130203
Download citation file: